Janet M Hall, NP
Nurse Practitioner · Castro Valley
- Medicare standing
- 2 flags on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
On the public record
- California licence: Delinquent
- 1 Medical Board action on record
Offices
2 locations · Epic Care · Stanford Health Care
Hospitals listed: Eden Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Janet M Hall’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C18940 · Delinquent
Licence status: Delinquent · since 1957 · expires 2023-04-30 · Washington University School of Medicine.
License renewal fee has not been paid. No practice is permitted.
Matched on the licence number without its letter prefix; check the name before relying on it.
Public record actions
| 2002-03-08 | Board disciplineDiscipline | Surrender of license. · 11 1999104515 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Money from drug and device companies
$2,127 in 2025
| 2025 | 32 | 91 | None | $2,127 |
| 2024 | 33 | 90 | None | $2,657 |
| 2021 | 2 | 2 | None | $41 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Tagrisso | $241 | 9 payments
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $216 | 17 payments
|
| Celgene | Reblozyl | $171 | 7 payments
|
| Pfizer | Ibrance | $144 | 5 payments
|
| GlaxoSmithKline | Jemperli | $133 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $122 | 5 payments
|
See all 85 published payments
| Array Biopharma | Meals · 2025-12-30 | Braftovi | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-16 | Tagrisso | $31 |
| Celgene | Meals · 2025-12-09 | Reblozyl | $24 |
| Secura Bio | Meals · 2025-12-05 | Copiktra | $21 |
| Pfizer | Meals · 2025-12-01 | Xtandi | $20 |
| Regeneron Healthcare Solutions | Meals · 2025-11-25 | Lynozyfic | $33 |
| Novocure | Meals · 2025-11-21 | Optune Lua (Novottf-200t) | $27 |
| Celgene | Meals · 2025-11-18 | Reblozyl | $21 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-13 | Fruzaqla | $27 |
| GlaxoSmithKline | Meals · 2025-11-07 | Ojjaara | $19 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-04 | Opdivo | $30 |
| GlaxoSmithKline | Meals · 2025-10-14 | Jemperli | $29 |
| Incyte | Meals · 2025-10-02 | Monjuvi | $25 |
| Pfizer | Meals · 2025-09-25 | Elrexfio | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-23 | Opdivo | $26 |
| Fennec Pharmaceuticals | Meals · 2025-09-19 | Fyarro | $20 |
| Genzyme | Meals · 2025-09-18 | Ayvakit | $64 |
| Eisai | Meals · 2025-09-16 | Lenvima | $28 |
| Celgene | Meals · 2025-09-04 | Reblozyl | $33 |
| GlaxoSmithKline | Meals · 2025-09-02 | Ojjaara | $17 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-29 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-08-29 | Iclusig | $25 |
| Astellas Pharma US | Education · 2025-08-27 | None | $100 |
| Karyopharm Therapeutics | Meals · 2025-08-19 | Xpovio | $32 |
| Daiichi Sankyo | Meals · 2025-08-12 | Enhertu | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-12 | None | $14 |
| Caris MPI | Meals · 2025-08-08 | Mi Cancer Seek | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-07-31 | Fruzaqla | $36 |
| Pfizer | Meals · 2025-07-29 | Ibrance | $26 |
| GlaxoSmithKline | Meals · 2025-07-24 | Jemperli | $28 |
| GlaxoSmithKline | Meals · 2025-07-24 | Jemperli | $17 |
| Coherus Oncology | Meals · 2025-07-16 | Loqtorzi | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-15 | Enhertu | $24 |
| Recordati Rare Diseases Inc. | Meals · 2025-07-11 | Enjaymo | $23 |
| Genentech USA | Meals · 2025-07-03 | Polivy | $25 |
| Novartis Pharmaceuticals | Meals · 2025-07-01 | Kisqali | $29 |
| Array Biopharma | Meals · 2025-06-27 | Xalkori | $36 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-26 | Opdivo | $20 |
| Novartis Pharmaceuticals | Meals · 2025-05-23 | Kisqali | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-13 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-13 | Iclusig | $22 |
| Celgene | Meals · 2025-05-06 | Reblozyl | $31 |
| Incyte | Meals · 2025-05-01 | Monjuvi | $29 |
| Lilly USA | Meals · 2025-04-25 | Verzenio | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-22 | Calquence | $26 |
| Eisai | Meals · 2025-04-18 | Lenvima | $26 |
| PharmaEssentia USA | Meals · 2025-04-17 | Besremi | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-15 | Imfinzi | $35 |
| GlaxoSmithKline | Meals · 2025-04-10 | Ojjaara | $24 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-08 | Enhertu | $30 |
| Celgene | Meals · 2025-04-04 | Reblozyl | $1 |
| Celgene | Meals · 2025-04-04 | Reblozyl | $33 |
| Sobi | Meals · 2025-04-03 | Vonjo | $35 |
| Pfizer | Meals · 2025-04-01 | Ibrance | $33 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-31 | Ninlaro | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-31 | Ninlaro | $7 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-31 | Iclusig | $11 |
| Legend Biotech USA | Meals · 2025-03-28 | Carvykti | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-25 | Opdivo | $20 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-20 | Fruzaqla | $2 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-20 | Fruzaqla | $29 |
| Kite Pharma | Meals · 2025-03-18 | Yescarta | $14 |
| Janssen Biotech | Meals · 2025-03-14 | Rybrevant | $31 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-11 | Ninlaro | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-11 | Ninlaro | $7 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-11 | Iclusig | $21 |
| Genentech USA | Meals · 2025-03-06 | Venclexta | $32 |
| Celgene | Meals · 2025-02-27 | Reblozyl | $29 |
| Geron | Meals · 2025-02-25 | Rytelo | $35 |
| Secura Bio | Meals · 2025-02-20 | Copiktra | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-20 | Lynparza | $24 |
| Merck Sharp & Dohme | Meals · 2025-02-18 | Keytruda | $25 |
| Novartis Pharmaceuticals | Meals · 2025-02-13 | Scemblix | $29 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-11 | Fruzaqla | $1 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-11 | Fruzaqla | $5 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-11 | Fruzaqla | $18 |
| Regeneron Healthcare Solutions | Meals · 2025-02-07 | Libtayo | $37 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-06 | Opdivo | $26 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-30 | None | $29 |
| Spectrum Pharmaceuticals | Meals · 2025-01-27 | Rolvedon | $27 |
| Novartis Pharmaceuticals | Meals · 2025-01-24 | Kisqali | $32 |
| Pfizer | Meals · 2025-01-23 | Ibrance | $36 |
| Incyte | Meals · 2025-01-21 | Monjuvi | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-08 | Lynparza | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-06 | Tagrisso | $30 |
See earlier years (2024, 2021)
2024: $2,657
| E.R. Squibb & Sons L.L.C. | Opdivo | $364 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $264 | 10 payments
|
| Merck Sharp & Dohme | Keytruda | $257 | 9 payments
|
| Novartis Pharmaceuticals | Fabhalta | $195 | 7 payments
|
| Aveo Pharmaceuticals | Fotivda | $131 | 3 payments
|
| Stemline Therapeutics | Orserdu | $122 | 1 payment
|
| Incyte | Monjuvi | $111 | 5 payments
|
| Pfizer | Inlyta | $106 | 4 payments
|
| Abbvie | Imbruvica | $105 | 5 payments
|
| Astellas Pharma US | None | $100 | 1 payment
|
| Janssen Biotech | Rybrevant | $72 | 2 payments
|
| Sobi | Vonjo | $66 | 2 payments
|
| Coherus Biosciences | Udenyca | $61 | 2 payments
|
| GlaxoSmithKline | Ojjaara | $57 | 2 payments
|
| Genmab U.S. | Epkinly | $56 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $56 | 3 payments
|
| Agios Pharmaceuticals | Pyrukynd | $52 | 2 payments
|
| Genzyme | Sarclisa | $49 | 2 payments
|
| Eisai | Lenvima | $47 | 2 payments
|
| Blueprint Medicines | Ayvakit | $46 | 1 payment
|
| BeiGene USA | Brukinsa | $41 | 2 payments
|
| Array Biopharma | Lorbrena | $29 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $28 | 1 payment
|
| PharmaEssentia USA | Besremi | $27 | 1 payment
|
| SpringWorks Therapeutics | Ogsiveo | $27 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Vitrakvi | $26 | 1 payment
|
| Kyowa Kirin | Poteligeo | $25 | 1 payment
|
| Taiho Oncology | Lonsurf | $25 | 1 payment
|
| Genentech USA | Itovebi | $25 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $24 | 1 payment
|
| Daiichi Sankyo | Enhertu | $24 | 1 payment
|
| Servier Pharmaceuticals | None | $21 | 1 payment
|
| Puma Biotechnology | None | $18 | 1 payment
|
2021: $41
| Genentech USA | Venclexta | $22 | 1 payment
|
| Bioventus | Gelsyn-3 | $19 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 6.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1538390687
- Licence
- CA 18940, CA 482996California C18940: Delinquent · expires 2023-04-30
- Group
- Epic Care · Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2009-08-06
- NPI last updated
- 2024-03-14
- NPI record certified
- 2024-03-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 218 De Anza Blvd, San Mateo, CA, 94402